As part of the National Institutes of Health’s Research Evaluation and Commercialization Hubs program, the State University of New Jersey will launch the Rutgers Optimizes Innovation - or ROI - Program, to be supported by $4 million over four years.

Currently, 180,000 New Jerseyans, and five million nationwide, have the disease for which a cure remains elusive.

The $39 million investment at Raritan Bay Medical Center will encompass 24,000 square feet – more than double its current footprint.

“Fresenius Kidney Care is a worldwide leader in the treatment of renal disease, and by working together, our current and future patients can continue to receive high-quality, compassionate treatment and care,” said Joseph Devine, president, Jefferson Health New Jersey, and chief experience officer, Jefferson Health.

According to the health care system, the new installation, along with its previously installed ground-mounted system, make it the largest solar-powered hospital in the state.

The move is part of the network’s comprehensive strategy to improve behavioral health care throughout New Jersey.

The bipartisan legislation would allow the FDA to partner with universities and authorize $80 million in funding to support the effort.

A panel of experts discussed advocacy and policy reforms, health care setting strategies, vaccination opportunities, incarcerated- and reentry-based screening and treatment, and other testing and treatment initiatives currently underway to eliminate a disease that affects all New Jersey residents, particularly in southern counties.

Dr. David Livingston, who is also a professor and the chief of the trauma division at Rutgers New Jersey Medical School, was elected to a one-year term as president of the American Association for the Surgery of Trauma.

Accountable Care Organizations throughout New Jersey are cutting costs for the delivery of services to Medicare beneficiaries, savings that are tracked by the Centers for Medicare and Medicaid Services under the Medicare Shared Savings Program.

The Hackensack Meridian Health Care facility is one of only three hospitals in the country that currently has access to the Impella 5.5 with SmartAssist from Abiomed Inc.

The smart shoe insert can monitor the foot health of a person living with diabetes and sends data to a companion app which can be accessed by the patient and shared with their health care provider.